↓ Skip to main content

The EMIF-AD PreclinAD study: study design and baseline cohort overview

Overview of attention for article published in Alzheimer's Research & Therapy, August 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)

Mentioned by

news
2 news outlets
twitter
2 tweeters

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The EMIF-AD PreclinAD study: study design and baseline cohort overview
Published in
Alzheimer's Research & Therapy, August 2018
DOI 10.1186/s13195-018-0406-7
Pubmed ID
Authors

Elles Konijnenberg, Stephen F. Carter, Mara ten Kate, Anouk den Braber, Jori Tomassen, Chinenye Amadi, Linda Wesselman, Hoang-Ton Nguyen, Jacoba A. van de Kreeke, Maqsood Yaqub, Matteo Demuru, Sandra D. Mulder, Arjan Hillebrand, Femke H. Bouwman, Charlotte E. Teunissen, Erik H. Serné, Annette C. Moll, Frank D. Verbraak, Rainer Hinz, Neil Pendleton, Adriaan A. Lammertsma, Bart N. M. van Berckel, Frederik Barkhof, Dorret I. Boomsma, Philip Scheltens, Karl Herholz, Pieter Jelle Visser

Abstract

Amyloid pathology is the pathological hallmark in Alzheimer's disease (AD) and can precede clinical dementia by decades. So far it remains unclear how amyloid pathology leads to cognitive impairment and dementia. To design AD prevention trials it is key to include cognitively normal subjects at high risk for amyloid pathology and to find predictors of cognitive decline in these subjects. These goals can be accomplished by targeting twins, with additional benefits to identify genetic and environmental pathways for amyloid pathology, other AD biomarkers, and cognitive decline. From December 2014 to October 2017 we enrolled cognitively normal participants aged 60 years and older from the ongoing Manchester and Newcastle Age and Cognitive Performance Research Cohort and the Netherlands Twins Register. In Manchester we included single individuals, and in Amsterdam monozygotic twin pairs. At baseline, participants completed neuropsychological tests and questionnaires, and underwent physical examination, blood sampling, ultrasound of the carotid arteries, structural and resting state functional brain magnetic resonance imaging, and dynamic amyloid positron emission tomography (PET) scanning with [18F]flutemetamol. In addition, the twin cohort underwent lumbar puncture for cerebrospinal fluid collection, buccal cell collection, magnetoencephalography, optical coherence tomography, and retinal imaging. We included 285 participants, who were on average 74.8 ± 9.7 years old, 64% female. Fifty-eight participants (22%) had an abnormal amyloid PET scan. A rich baseline dataset of cognitively normal elderly individuals has been established to estimate risk factors and biomarkers for amyloid pathology and future cognitive decline.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 75 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 16%
Researcher 10 13%
Student > Master 8 11%
Student > Bachelor 7 9%
Student > Doctoral Student 5 7%
Other 6 8%
Unknown 27 36%
Readers by discipline Count As %
Neuroscience 13 17%
Medicine and Dentistry 13 17%
Psychology 7 9%
Computer Science 4 5%
Nursing and Health Professions 2 3%
Other 5 7%
Unknown 31 41%

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2018.
All research outputs
#1,570,232
of 20,194,585 outputs
Outputs from Alzheimer's Research & Therapy
#296
of 1,040 outputs
Outputs of similar age
#36,852
of 296,048 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 20,194,585 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,040 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,048 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them